Samuraciclib

• Target:

  Others|||Apoptosis|||CDK

• Related Pathways:

  Cell Cycle/Checkpoint|||Others|||Apoptosis

• Bioactivity:

  Samuraciclib (CT7001) is a potent, selective, and orally active CDK7 inhibitor with an ATP-competitive nature, effectively inhibiting CDK7 with an IC50 of 41 nM. It demonstrates 45-fold, 15-fold (IC50 of 578 nM), 230-fold, and 30-fold selectivity over CDK1, CDK2, CDK5, and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values of 0.2-0.3 ?M and possesses anti-tumor effects [1] [2].

• Smiles:

  N(CC1=CC=CC=C1)C=2N3C(=C(C(C)C)C=N3)N=C(NC[C@@H]4[C@@H](O)CNCC4)C2

• Molecular Formula:

  C22H30N6O

• Molecular Weight:

  394.51

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1805833-75-3